Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line
docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes
compared to standard first-line docetaxel/prednisone treatment alone. This will be a
randomized, open-label, multicenter, international trial. Treatment will consist of
docetaxel/prednisone/custirsen vs. docetaxel/prednisone. A total of at least 1000 patients
will be randomized. Patients will be randomly assigned with equal probability to the two
arms.
Phase:
Phase 3
Details
Lead Sponsor:
Achieve Life Sciences OncoGenex Technologies
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries